Understanding how melanoma cells change and resist treatment
Transcriptional Reprogramming in Melanoma Plasticity
This study is looking at how advanced melanoma, a serious skin cancer, changes and becomes resistant to treatments, focusing on a protein called TFEB that might help us find better ways to help patients who aren't responding to current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10858175 on NIH RePORTER |
What this research studies
This research investigates advanced melanoma, a severe form of skin cancer, focusing on how melanoma cells adapt and become resistant to therapies. It explores the role of a specific protein, TFEB, which is crucial for cell differentiation and may influence how melanoma cells respond to treatment. By studying the molecular mechanisms behind these changes, the research aims to identify new strategies to improve treatment outcomes for patients who currently do not respond to existing therapies. Patients may have their tumor profiles analyzed to understand the relationship between TFEB activity and treatment resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced melanoma who have not responded to current therapies or have experienced a relapse.
Not a fit: Patients with early-stage melanoma or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that improve survival rates for patients with advanced melanoma.
How similar studies have performed: Other research has shown promising results in understanding the mechanisms of treatment resistance in melanoma, making this approach both relevant and potentially impactful.
Where this research is happening
Philadelphia, United States
- Wistar Institute — Philadelphia, United States (Active)
Researchers
- Principal investigator: Liang, Chengyu — Wistar Institute
- Study coordinator: Liang, Chengyu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.